Further Clinical Research Will ‘Push the Needle Forward’ for and Encourage Clinical Adoption ctDNA in Colorectal Cancer

Video

An expert from Natera describes where future research needs to be focused for circulating tumor DNA testing in patients with colorectal cancer following the CIRCULATE-Japan study.

Additional clinical research findings on circulating tumor DNA (ctDNA) as a biomarker for patients with colorectal cancer (CRC) could better support guidelines and lead to a wider scale adoption of the strategy in practice, according to according to Minetta Liu, MD.

In an interview with CancerNetwork®, Liu, chief medical officer of oncology at Natera, discussed how the additional findings could help to support treatment de-escalation in the population and push the needle forward for patients and providers, alike.

Additionally, Liu spoke to the patient demographics of the CIRCULATE-Japan study and highlighted similarities within the United States population. She also touched on similar ongoing studies taking place in the United States assessing ctDNA for cohorts of patients with CRC.

Transcript:

We really need to demonstrate clinical utility. We have strong suggestions from [the GALAXY] observational cohort, and that's really the potential for impact in clinical practice. But to really support guidelines and true clinical adoption for all of these patients and hopefully de-escalate chemotherapy in patients, we need to demonstrate this in clinical utility trials. Those are ongoing. Support for those trials, both in Japan and the U.S where these studies are ongoing, is really what's going to push the needle forward for patients and our providers.

[CIRCULATE-Japan] was performed only in Japan, but the demographics of that patient population are roughly comparable to the United States population. We do have the BESPOKE CRC study [NCT04264702], an observational registry study in the United States. These findings, again, which are following usual care and physician's choice, will help corroborate the observational findings from GALAXY. And then we have parallel, prospective, randomized phase 3 trials for clinical utility in both populations: CIRCULATE-Japan and CIRCULATE-US.

Reference

Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with clinical stage II-IV resectable colorectal cancer. Nature Medicine. Published online January 16, 2023. doi:10.1038/s41591-022-02115-4

Related Videos
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Stacey Cohen, MD, an expert on colorectal cancer
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
A panel of 5 experts on colorectal cancer
Aparna Parikh, MD, an expert on colorectal cancer
Related Content
Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.

Adagrasib Combo Yields Encouraging Responses in KRAS G12C–Mutated CRC

April 9th 2024
Article

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.

New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.

Joleen Hubbard, MD, Highlights The “Exciting Space” Of Metastatic CRC

December 11th 2023
Podcast

New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.

CRC-Associated Gene Alteration May Raise Likelihood of Other Solid Tumors

April 3rd 2024
Article

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.

Microbiome Signature Differences May Impact Rectal Cancer Treatment Effect

March 30th 2024
Article

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.

A2B530 Earns FDA Orphan Drug Designation in CEA+ Colorectal Cancer

March 6th 2024
Article

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.